west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "糖尿病周围神经病变" 11 results
  • Autologous Transplantation of Stem Cells for Diabetic Peripheral Neuropathy: A Systematic Review

    Objective To systematically review the effectiveness and safety of autologous implantation of stem cells for diabetic peripheral neuropathy (DPN). Methods Randomized controlled trials on relevant studies were retrieved in databases including CBM (1978-2011.6), CNKI (1979-2011.6), MEDLINE (1950-2011.6), PubMed (1950-2011.6), EMbase (1970-2011.6) and The Cochrane Library (Issue 3, 2011). References of the included studies were also retrieved. Two reviewers independently screened literature according to the inclusion and exclusion criteria, extracted data, and assess the methodological quality of the included studies. Then, meta-analysis was performed using RevMan 5.0 software.Results Four RCTs involving 68 patients (136 limbs) were included, most of which were low in methodological quality. The results of meta-analysis indicated that, autologous stem cell therapy improved or even eliminated DPN symptoms including pain, numbness, and cold sensation in the limbs, intermittent limping, and rest pain. Compared with the routine therapy, autologous stem cell therapy improved tibial sensory nerve conduction velocity (MD=5.75, 95%CI 3.86 to 7.64, Plt;0.000 01), tibial motor nerve conduction velocity (MD=4.04, 95%CI 0.90 to 7.18, P=0.001), sural sensory nerve conduction velocity (MD=7.47, 95%CI 4.00 to 10.94, Plt;0.000 1), and sural motor nerve conduction velocity (MD=3.38, 95%CI 0.07 to 7.58, P=0.05), with no adverse reaction reported. Conclusion Current evidence shows that, autologous stem cell therapy is effective in treating DPN. Due to the lack of high quality studies, more high quality RCTs are needed to verify the above conclusion.

    Release date: Export PDF Favorites Scan
  • Effects of Venlafaxine and Carbamazepine for Painful Peripheral Diabetic Neuropathy: A Randomized, Double-blind and Double-dummy, Controlled Multi-center Trial

    Objective To evaluate the safety and efficacy of venlafaxine and carbamazepine on painful peripheral diabetic neuropathy. Methods This was a randomized, parallel-group, double-blind, double-dummy clinical trial. 132 patients a venlafaxine group (n=66) and a carbamazepine group (n=66) with painful peripheral diabetic neuropathy were recruited from 3 clinical centers. The venlafaxine group took venlafaxine 25 mg plus one dummy carbamazepine tablet twice a day and the carbamazepine group took carbamazepine 0.1 g plus one dummy venlafaxine tablet twice a day both for 2 weeks. The primary efficacy measurement consisted of a numeric pain intensity scale and the secondary measurement assessed quality of life. Results One hundred and nineteen patients completed the trial. Venlafaxine was superior to carbamazepine in improving mean pain intensity scores at 5,7,10 and 14 days by per-protocol analysis (P=0.02, P=0.03, P=0.003 and P=0.001 respectively). The effects of venlafaxine on the improvement in the total quality of life scores were better than those of carbamazepine at 10 and 14 days (P=0.02 and P=0.01 respectively). Sleep interference and mood were improved by both venlafaxine and carbamazepine, but the efficacy of venlafaxine was superior to that of carbamazepine. The common adverse events of venlafaxine included mild gastrointestinal discomfort, dizziness and somnolence. The frequency of adverse events in the venlafaxine group was about 43.9% (4 patients withdrew because of adverse events) and in the carbamazepine group about 25.76% (2 patients withdrew because of adverse events) (P =0.06). Conclusions Venlafaxine and carbamazepine are effective in the treatment of painful diabetic neuropathy, venlafaxine is superior to carbamazepine in improving pain and quality of life. Both drugs may be safe and well tolerated.

    Release date:2016-09-07 02:18 Export PDF Favorites Scan
  • Effects of Methylcobalamin on Diabetic Peripheral Neuropathy: A Systematic Review

    Objective To review systematically whether there is enough existing evidence that methylcobalamin is effective and safe in the treatment of the patients with diabetic peripheral neuropathy.Methods A Cochrane systematic review of all relevant randomized or quasi-randomized controlled trials of methycobalamin for diabetic peripheral neuropathy was performed. Clinical trials were searched from Cochrane Controlled Trials Register (Issue 4, 2003), MEDLINE (January 1966 to January 2004), EMBASE (January 1980 to January 2004), the Chinese Biological Medicine Database (1978 to January 2004), the Chinese Science and Technology Journal Full-text Database (1989 to January 2004) and references of all included trials. The selection of studies, data extraction and assessment of methodological quality were performed independently by two reviewers. The following outcomes were assessed: effectiveness of clinical signs and symptoms, sensory nerve and motor nerve conduction velocities and serious adverse events of methylcobalamin. Results Thirty randomized clinical trials including 1 949 patients met the inclusion criteria. The quality of the most included trials was of low level. The "funnel plot" of the comparison of thirteen studies of methylcobalamin with other B Vitamins studies showed symmetry, which indicated less possible publication bias and the result was partly reliable, but it could not indicate the whole publication biases. The results of meta-analysis indicated that methylcobalamin showed significantly positive effects on the improvement of the signs and symptoms of peripheral neuropathy, and the effects were better than the other vitamin B agents. The increase of some nerves conduction velocities by methylcobalamin was better than by the other vitamin B. No serious adverse events were observed during the treatment period.Conclusions Methylcobalamin appears to be a safe and effective treatment on diabetic peripheral neuropathy. However, the evidence is not b because of the low quality of most trials. Rigorously designed, randomized, double-blinded, placebo-controlled trials of methylcobalamin for diabetic peripheral neuropathy are needed to further assess the effect.

    Release date:2016-09-07 02:26 Export PDF Favorites Scan
  • Tetramethylpyrazine for Diabetic Peripheral Neuropathy: A Systematic Review

    Objective To evaluate the efficacy and safety of tetramethylpyrazine (TMP) for diabetic peripheral neuropathy (DPN). Methods Randomized controlled trials were identified from CBM (1978-2003.3), TCMLRS (1980-2003.3), Medline (1970-2003.3), EMbase (1970-2003.3) and Cochrane Library (issue 3, 2003). We handsearched Journal of Traditional Chinese Medicine (1990-2002), New Chinese Medicine (1990-2002), Chinese Journal of Integrated Traditional and Western Medicine (1990-2002) and Research of Traditional Chinese Medicine (1990-2002). Papers of the controlled trials of clinical therapeutic studies on DPN treatment by Chinese medicine herb TMP were included and analyzed according to the criteria of the Cochrane Handbook in 1997. Results Six RCTs involving 669 patients were included, with all trials of low methodological quality. Meta-analysis indicated TMP was more effective than western medicine on pain or numbness of extremities of DPN [The pooled OR = 10.12, 95%CI (6.70 to15.28), P=0.000] and motor nerve conduction velocity change of common peroneal nerves and median nerves . Only one trial reported the side effects of TMP, such as dizziness and headache. Conclusions Based on the review, TMP infusion may have positive effect on DPN. However, the evidence is not b enough due to the general low methodological quality, so we can’t draw a reliable conclusion about the effects of TMP for DPN at the moment. Further large randomized, double blind, placebo-controlled trial are needed.

    Release date:2016-09-07 02:28 Export PDF Favorites Scan
  • Puerarin in the Treatment of Diabetic Peripheral Neuropathy: A Systematic Review

    Objective To systematically evaluate the effectiveness and safety of Puerarin on diabetic peripheral neuropathy. Methods A systematic review and evaluation of all available relevant randomized or quasi-randomized controlled trials of Puerarin for diabetic peripheral neuropathy from Cochrane Controlled Trials Register (150 issue of 2003), Medline (1966-2003. 2), EMbase (1984-2001. 12. 4), and the Chinese Biological Medicine Database (1978-2003. 2) were performed. The selection of studies, data extraction, and assessment of methodological quality were performed independently by two reviewers. The following outcomes were assessed: effectiveness of clinical symptoms, sensory nerve and motor nerve conduction velocities, and severe adverse events of Puerarin. Results Ten randomized controlled clinical trials including 726 patients met the inclusion criteria. At the end of the treatment, compared to general treatment or vitamin B, Puerarin showed significant positive effects on the total effect rate of therapy and increased peripheral nerve conduction velocity. No severe adverse events were observed during the treatment period. However, most included trials show some degree of study design or analysis defect. Conclusions Our analysis suggests that Puerarin appears to be an effective and safe treatment for diabetic peripheral neuropathy. However, due to the low quality trials included in this review, more rigorously designed, randomized, double-blind, placebo-controlled trials of Puerarin for diabetic peripheral neuropathy are needed to further assess its usefulness in diabetes peripheral neuropathy patients.

    Release date:2016-09-07 02:28 Export PDF Favorites Scan
  • 缺氧诱导因子-1α与糖尿病周围神经病变

    糖尿病周围神经病变是糖尿病最常见的慢性并发症之一。缺血、缺氧在糖尿病周围神经病变中起着重要作用,而缺氧可刺激缺氧诱导因子(HIF)-1α表达增强。HIF-1α可增强细胞对低氧的适应能力,对多种细胞具有保护作用,亦可直接抑制神经细胞凋亡以及调节其下游基因血管内皮生长因子、促红细胞生成素等的表达,可能对糖尿病周围神经发挥保护作用。

    Release date:2016-09-08 09:11 Export PDF Favorites Scan
  • 甲钴胺联合胰激肽原酶片治疗糖尿病周围神经病变

    目的 探讨甲钴胺联合胰激肽原酶片治疗糖尿病周围神经病变的疗效。 方法 2003年5月-2009年3月将42例社区糖尿病周围神经病变患者随机分为治疗组21例,对照组21例。对照组单用甲钴铵注射液治疗,治疗组采用甲钴铵联合胰激肽原酶片治疗。3个月后观察比较两组疗效。 结果 治疗组显效10例,有效8例,无效3例,总有效率85.7%。对照组显效4例,有效6例,无效11例,总有效率47.6%。 结论 甲钴胺联合胰激肽原酶片治疗糖尿病周围神经病变近期疗效较好。

    Release date:2016-09-08 09:47 Export PDF Favorites Scan
  • 中药足浴对糖尿病周围神经病变的疗效比较

    目的 探讨中药足浴治疗糖尿病周围神经病变(DPN)的临床疗效。 方法 2008年7月-2009年7月,110例DPN患者随机分为中药足浴治疗组(50例)和常规治疗组(60例),观察两组患者的临床疗效及肌电图变化情况。 结果 中药足浴治疗组和常规治疗组总有效率分别为82.0%和50.0%,两组间比较有显著性差异(P<0.05)。 结论 中药足浴治疗可有效改善DPN患者的临床症状和神经传导速度。

    Release date:2016-09-08 09:47 Export PDF Favorites Scan
  • Efficacy of Combination of Pancreatic Kinionogenase and Mecobalamin on Diabetic Peripheral Neuropathy

    ObjectiveTo study the effect of combined treatment using pancreatic kinionogenase enteric-coated tab and mecobalamin injection on diabetic peripheral neuropathy (DPN) patients. MethodsWe collected 84 subjects with DPN who received treatment from January 2012 to December 2012 in our hospital, and we randomly divided them into treatment group (42 subjects, using pancreatic kinionogenase enteric-coated tab and methylcobalamin injection) and control group (42 subjects, using mecobalamine only). Subjects in the treatment group were given oral pancreatic kininogenase at 120 unit/times and 3 times/day, and methylcobalamin intravenous injection at 1 mg/day for 14 days. Subjects in the control group were only given methylcobalamin intravenous injection at 1 mg/day for 14 days. ResultsIn the treatment group, 22 subjects showed excellent, 19 subjects effective and 1 subject ineffective outcome. In the control group, 8 subjects showed excellent, 22 effective and 12 ineffective outcome. The difference between the two groups is statistically significant (P<0.01). Compared with no treatment, the nerve conduction velocity in both the two groups has been improved. The improvement in the treatment group is significantly better than that of the control group (P<0.01), and all of them had no obvious adverse reaction during the treatment. ConclusionThe combined treatment using pancreatic kinionogenase enteric-coated tab and methylcobalamin injection on DPN is better than using methylcobalamin only.

    Release date: Export PDF Favorites Scan
  • 腺苷钴胺穴位注射联合穴位按摩干预糖尿病周围神经病变疗效观察

    目的探讨腺苷钴胺穴位注射联合穴位按摩对糖尿病周围神经病变的疗效。 方法选择2011年3月-2012年3月收治的糖尿病周围神经病变患者70例,随机分为2组各35例。干预组患者给予腺苷钴胺0.5 mg双侧足三里注射,3次/周,联合双下肢足三里、阴陵泉、三阴交穴位按摩;对照组患者给予腺苷钴胺0.5 mg肌肉注射。两组患者治疗4周后测量运动神经传导速度(MCV)并采用中医症状分级量化标准评估患者症状缓解程度。 结果两组患者MCV比较,干预组为(43.90±3.67) m/s,对照组为(40.20±3.85)m/s,两组差异有统计学意义(t=4.115,P<0.001);两组患者中医症状分级量化标准评估比较,干预组为(23.39±6.09)分,对照组为(27.09±5.75)分,两组比较差异有统计学意义(t=-2.614,P=0.011)。 结论腺苷钴胺穴位注射联合穴位按摩治疗糖尿病周围神经病变疗效好,操作方便,患者依从性高,值得推广。

    Release date: Export PDF Favorites Scan
2 pages Previous 1 2 Next

Format

Content